Utah Medical Products Q3 Net Income Rises 6%; Nine-Month Revenue Falls 12%
Utah Medical Products reported Q3 2026 revenue of $8.621M, down 12.1% YoY, with net income up 5.9% to $2.787M. Nine-month revenue fell 12.2% to $25.873M, and net income declined 7.4% to $8.077M. The company attributed the revenue decline to lost customers and weaker sales in key products. Management projected a full-year 2026 sales decline of about 7%.
How this was made
The 30-second read
Why it matters
The earnings miss and lowered full-year sales outlook may trigger a sell‑off in the stock, typical for micro‑cap medical device firms.
Market read
Micro‑cap earnings release with weaker revenue, likely prompting short‑term price decline.
What to watch
Recent acquisition of Orion UK business could provide longer-term growth not reflected in the short-term earnings.
Background
Utah Medical Products (UTMD) filed an 8‑K reporting its Q3 2026 results, highlighting revenue decline and a modest net income rise.
Ticker impact
Q3 2026 earnings released showing revenue down 12% YoY and modest net income increase, indicating weaker sales trends.
likely pressure as the market prices in weaker sales and guidance of a full-year decline near 7%
Earnings miss on revenue and guidance downgrade typically lead to short-term price weakness for microcaps.
Market effects
Signals softness in the medical device sector, particularly for neonatal and contraceptive devices.
Limited to U.S. small-cap healthcare investors.
Minimal global impact.
Counterpoint
Potential upside if new biopharma customers accelerate adoption faster than expected.
Key entities
- CompanyUtah Medical Products
Medical device manufacturer reporting Q3 earnings.